Detecting amyloid-ß positivity using regions of interest from structural magnetic resonance imaging.

BACKGROUND AND PURPOSE: Alzheimer disease (AD) is the most common type of dementia. Amyloid-ß (Aß) positivity is the main diagnostic marker for AD. Aß positron emission tomography and cerebrospinal fluid are widely used in the clinical diagnosis of AD. However, these methods only assess the concentrations of Aß, and the accessibility of these methods is thus relatively limited compared with structural magnetic resonance imaging (sMRI). METHODS: We investigated whether regions of interest (ROIs) in sMRIs can be used to predict Aß positivity for samples with normal cognition (NC), mild cognitive impairment (MCI), and dementia. We obtained 846 Aß negative (Aß-) and 865 Aß positive (Aß+) samples from the Alzheimer's Disease Neuroimaging Initiative database. To predict which samples are Aß+, we built five machine learning models using ROIs and apolipoprotein E (APOE) genotypes as features. To test the performance of the machine learning models, we constructed a new cohort containing 97 Aß- and 81 Aß+ samples. RESULTS: The best performing machine learning model combining ROIs and APOE had an accuracy of 0.798, indicating that it can help predict Aß+. Furthermore, we searched ROIs that could aid our prediction and discovered that an average left entorhinal cortical region (L-ERC) thickness is an important feature. We also noted significant differences in L-ERC thickness between the Aß- and Aß+ samples even in the same diagnosis of NC, MCI, and dementia. CONCLUSIONS: Our findings indicate that ROIs from sMRIs along with APOE can be used as an initial screening tool in the early diagnosis of AD.

Prediction of anti-vascular endothelial growth factor agent-specific treatment outcomes in neovascular age-related macular degeneration using a generative adversarial network.

To develop an artificial intelligence (AI) model that predicts anti-vascular endothelial growth factor (VEGF) agent-specific anatomical treatment outcomes in neovascular age-related macular degeneration (AMD), thereby assisting clinicians in selecting the most suitable anti-VEGF agent for each patient. This retrospective study included patients diagnosed with neovascular AMD who received three loading injections of either ranibizumab or aflibercept. Training was performed using optical coherence tomography (OCT) images with an attention generative adversarial network (GAN) model. To test the performance of the AI model, the sensitivity and specificity to predict the presence of retinal fluid after treatment were calculated for the AI model, an experienced (Examiner 1), and a less experienced (Examiner 2) human examiners. A total of 1684 OCT images from 842 patients (419 treated with ranibizumab and 423 treated with aflibercept) were used as the training set. Testing was performed using images from 98 patients. In patients treated with ranibizumab, the sensitivity and specificity, respectively, were 0.615 and 0.667 for the AI model, 0.385 and 0.861 for Examiner 1, and 0.231 and 0.806 for Examiner 2. In patients treated with aflibercept, the sensitivity and specificity, respectively, were 0.857 and 0.881 for the AI model, 0.429 and 0.976 for Examiner 1, and 0.429 and 0.857 for Examiner 2. In 18.5% of cases, the fluid status of synthetic posttreatment images differed between ranibizumab and aflibercept. The AI model using GAN might predict anti-VEGF agent-specific short-term treatment outcomes with relatively higher sensitivity than human examiners. Additionally, there was a difference in the efficacy in fluid resolution between the anti-VEGF agents. These results suggest the potential of AI in personalized medicine for patients with neovascular AMD.

SDGCCA: Supervised Deep Generalized Canonical Correlation Analysis for Multi-Omics Integration.

Integration of multi-omics data provides opportunities for revealing biological mechanisms related to certain phenotypes. We propose a novel method of multi-omics integration called supervised deep generalized canonical correlation analysis (SDGCCA) for modeling correlation structures between nonlinear multi-omics manifolds that aims at improving the classification of phenotypes and revealing the biomarkers related to phenotypes. SDGCCA addresses the limitations of other canonical correlation analysis (CCA)-based models (such as deep CCA, deep generalized CCA) by considering complex/nonlinear cross-data correlations between multiple (≥2) modalities. Although there are a few methods to learn nonlinear CCA projections for classifying phenotypes, they only consider two views. Methods extended to multiple views either do not perform classification or do not provide feature ranking. In contrast, SDGCCA is a nonlinear multi-view CCA projection method that performs classification and ranks features. When we applied SDGCCA in predicting patients with Alzheimer's disease (AD) and discrimination of early- and late-stage cancers, it outperformed other CCA-based and other supervised methods. In addition, we demonstrate that SDGCCA can be applied for feature selection to identify important multi-omics biomarkers. On applying AD data, SDGCCA identified clusters of genes in multi-omics data, well known to be associated with AD.